Copyright
©The Author(s) 2020.
World J Clin Cases. May 26, 2020; 8(10): 1767-1792
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1767
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1767
Disease model/ physiology | Effect | Mechanism | Compound | Dose/IC50 /Ki. | Ref. | |
↑↑↑ | ↓↓↓ | |||||
Atherosclerosis | Anti-atherosclerotic | Ang1-7, ANG, NO, eNOS | IL-1β, TNF-α, and IL-6 | OA | 0-160 µmol/L | [29] |
Immune suppression | ZFP-459, FMO-2 | OA-Xs | [116] | |||
T. cruzi, L. braziliensis, L. infantum | Anti-protozoal | - | OA, OA-X | 3.3-89 µmol/L | [138] | |
Leishmania species | Anti-parasitic | CYP51, ergosterol synthesis | OA | 30.4-68.7 µmol/L | [139] | |
P. berghei malaria | Anti-malaria | TNF-α, IL-6, IL-10, hepcidin | OA | 34 mg/kg, 5 d | [140] | |
HBV | Anti-viral | HBS-Ag, HBE-Ag, HBV DNA replication | OA-Xs | 8.6-38.1 | [141] | |
Allergic conjunctivitis | Anti-allergic and anti-inflammatory | IL-10 | Allergen-specific IgGs, sPLA2 -IIA, Th2, RWP-T-Cell dif, EOL-1 , IL-33, MCP-1 | OA | 50 mg/kg·d, 5 d after sens | [142] |
Asthma | Anti-asthmatic | tBET, FOX-P3 | IL-5, IL-13, IL-17, OVA-IgE, GATA-3, RORγt, | OA | 2 or 20 mg/kg·2 d, 5 wk | [143] |
Atherosclerosis | Anti-artherosclerotic | NRF-2, HO-1, SOX, NO, CAT, GPX, GSH, HDL | LOX, NADPH Ox, LDL, TC, TG, pGP91, pP67, pP7 | OA | 15-50 mg/kg·d, 3 wk; 5-20 µmol/L | [144] |
Vascular injury | Prevent endothelial oxLDL effect | CASP, NO, pAKT, peNOS, | OA-Xn | 5 and 100 µmol/L | [145] | |
Low-density lipoprotein receptor knockout (LDLR −/− ) mice | Review Atherosclerotic | AdipoR1, PPAR-γ | AdipoR2, TC, LDL-C | OA | 25 mg/kg·d, 5 wk | [146] |
Myocardial injury | Cardioprotection, hyperglycemia-induced myocardial injury | CASP-3/9, BAX, pERK1/2, HOMER-1α, ERK1/2, SIRT1 | BCL-2, ROS | OA-Xn | 12.5-50 µmol/L | [147] |
Carotid artery injury | Proteccts diabetes induced artery injury | body weights, serum NO | endothelin 1, IL-1β, IL-6 , IL-18, NLRP-3, CASP-1 | OA | 100 mg/kg·d, 6 wk | [148] |
Vascular injury | Hypotensive | physiological data | physiological data | OA, OA-Xn | 0.1-100 µmol/L | [149] |
Hiperlipidemia | Anti-hiperlipidemic | 17 genes (microarray), CACNA-1B | TC, TG, HDLC, 4 genes | OA | 3 tablets/d , 4 wk | [150] |
Hiperlipidemia | Anti-hiperlipidemic likely via regulation of the miR-98-5p/PGC-1b axi | TC, TG, LDL, PGC-1b | OA | 20 mg/kg, 4 wk | [151] | |
Fertility | Recovered fertility | increasing the permeability of the germinal epithelium | OA | 30 mg/kg | [152] | |
Fertility | Infertility treatment | OCT-4, GDF-9, STRA-8, MVH, ZP-2, ZP-3, ITG-α6, TP-2, | SCP-3, ZP-1, ITG-β1 | OA | 3 µg/mL | [153] |
Fertility/Reproductive function | Rejuvenates testicular function | BCL-2 | pNF-κB, IL-1β , COX-2 TNF-α, H2AX, pP53, BAX, P38 | OA | 5-25 mg/kg·d, 24 wk | [154] |
Renal fibrosis | Attenuates renal fibrosis | NRF-2, HO, NQO-1, BAX, HSP-70 | BCL-2, | OA | N.R. | [155] |
Nephropathy | Prevent diabetic nephropathy | sINS, SOD, adiponectin | TG, BUN, Cr, TGF-β, SMAD1/2 | OA | 100 mg/kg·d, 20 wk | [156] |
Renal IRI | anti-Renal IRI | SOD, GPX, TT, eNOS, NRF-2, PPAR-γ, DDAHs | Cre, NGAL, TOS, NO, ADMA, NF-κB, ET-1 | OA-Xs | 20 mg/kg, 5 h before IR | [157] |
Nephritis Lupus/SLE | Inhibition of Th17 differentiation | Th17, IL-17A, serum dsDNA, ROR-γt | OA-Xs | 0-10 µmol/L, 50 mg/kg | [158] | |
MRSA | Anti-microbial | Microbe concentration | OA-Xs | 10-30 µg/mL | [159] | |
Circadian clock | Mediates circadian clock | CLOCK, ELO-VL3, TUBB-2A CLDN-1, BMA-1 | AMY-2A5, USP-2, PER-3,THRSP | OA | 0.01% diet | [160] |
Cisplatin induced nephrotoxicity | Prevent neprotoxicity | MAP-1A/AB, LC1 | CASP-3/9, PARP cleavage, ATG-5, ERK1/2, STAT3, NF-κB | OA | 10-40 mg/kg | [161] |
Dermatitis/TPA-treated mouse ears | Inhibit dermatitis | MPO, COX-2, iNOS, TNF-a, IL-1β, pP65 | OA-Xn | 2, 5 or 10 µmol/L | [162] | |
Diabetes induced cardiomyopathy | Prevent diabetic induced cardiomyopathy via Nrf2 | HO-1, SOD, NRF-2, | Glycogen, MDA, p-GS | OA | 80 mg/kg·2 d, 14 d | [163] |
Diabetic mesangial cell injury | Diabetic renal fibrosis | PI3K/AKT/mTOR | Autophagy, PTEN, | OA | 10 µmol/L | [164] |
Gut atrophy /piglet model | Prevent gut atrophy | TGR-5, FXR | OA | 50 mg/kg·d, 14 d | [165] | |
Immune suppression | Immune suppressive, anti-RA | IL-10 | collagen specific sIgG, CD4+ INF-γ, IL-17α, IL-2-/4/6/1β, TNF-α, GM-CSF, MCP-1 , MMP-1/3 | OA-Xs | 1-10 mg/kg 18 times between 28 and 53 d after the initial immunisation | [166] |
Immune suppression/glucocorticoid resistance | Protecting DEX induced GC impairment | Apoptosis, GR binding | GR-α | OA+I | 100 mg/kd·d, 21 d | [167] |
Longevity | DAF-16, SOD-3, HSP-16.2 CTL-1 | OA | 0-600 µmol/L·2 d | [168] | ||
Metal (MeHg) toxicity | Mitigate low-dose MeHg toxicity. | accumulation of metals in organs | OA-Xs | 40 µg/kg | [169] | |
Muscle Atrophy | Reduces denervation induced muscle atrophy | CNTF, JNK-2, STAT3 | OA-Xs | 0.2-1 µmol/L | [170] | |
Muscle atrophy | Anti-muscle atrophy | mTORC-1/P70, S6K, PAX-7, MYO-D, Myogenin | FOXO-1, MURF-1, Atrogi-n1 | OA-Xs | 1 µmol/L, 1-10 mg/kg | [171] |
Myocarditis - myocardial İnjury | EA myocarditis | IL-10, IL-33 | HW/BW, BPN, IK-17, IL-6, TNF-α , Galectin | OA | 50 mg/kg·d, 21 d or 65 d | [172] |
Obesity | Anti-obesity | octanoylated ghrelin production, PC-1/3, PC-2 | OA | 20-40 mg/kg, 7 d | [173] | |
Obesity | Improves gustatory perception of lipids and exerts protective effects in obesity | CD36 | blood insulin and glucose, hepat,c TG, IL-6 | OA | 0.005% (w/v) for 16 wk | [174] |
Renal injury | Prevent nephropathy | nNRF-2/tNRF-2, HO-1, KEAP-1, BAX | urinary 8-OHdG and 8-iso-PGF-2 α, BCL-2 | OA | N.R. | [175] |
Renal IRI | Anti-Renal IRI; antioxidant, anti-inflammatory, and anti-apoptotic activities | SOD, GPX, GSH, CAT, IL-10, NRF-2, GGLc | BUN, Cr, KIM-1, LDH, MDA, IL-6, INF-γ, MPO, | OA | 12.5-50 mg/kg·d, 15 d | [176] |
Sepsis | Lung damage, experimental sepsis | SOD, GPX, IL-6, IL-10, KC | iNOS, NRF-2, | OA | 10 mg/kg | [177] |
Vascular injury | Prevent oxidative stress induced cell injury by with AKT/eNOS signaling pathway | NO, SOD, CAT, CASP-3, FAS, FASL, BCL-2 | MDA, BAX | OA | [178] |
- Citation: Sen A. Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases. World J Clin Cases 2020; 8(10): 1767-1792
- URL: https://www.wjgnet.com/2307-8960/full/v8/i10/1767.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i10.1767